Strategic Collaboration with JW Therapeutics
Filed with ASX · · 3 pages · English
• Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene’s onCARlytics (CF33-CD19) oncolytic virus and JW’s CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. • The collaboration includes preclinical studies, followed by a Phase 1 investigatorinitiated trial (IIT) in China targeting difficult-to-trea
Earlier from Imugene
- S&P DJI Announces September 2025 Quarterly Rebalance
- Final Share Purchase Plan Allotment
- Appendix 4E and Annual Report
- Imugene Capital Raising Presentation
- Imugene Completes $22.5M Placement and c.$15M SPP
Later from Imugene
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
- FDA Supports Strategy Toward Registration for Azer-cel
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Trading Halt
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene